Department of Life Science & Biotechnology, College of Natural Sciences, Dong-eui University, Busan 614-714, Korea.
Arch Pharm Res. 2011 Jun;34(6):861-4. doi: 10.1007/s12272-011-0600-7.
Trimebutine has been used for treatment of both hypermotility and hypomotility disorders of the gastrointestinal (GI) tract, such as irritable bowel syndrome. In this issue, Tan et al. (2011) examined the concentration-dependent dual effects of trimebutine on colonic motility in guinea pig. The authors suggested that trimebutine attenuated colonic motility mainly through the inhibition of L-type Ca(2+) channels at higher concentrations, whereas, at lower concentrations, it depolarized membrane potentials by reducing BK(ca) currents, resulting in the enhancement of the muscle contractions. Trimebutine might be a plausible modulator of GI motility, which gives an insight in developing new prokinetic agents. Further studies to elucidate the effects of trimebutine on the interstitial cells of Cajal, the pacemaker in GI muscles would promote the therapeutic benefits as a GI modulator.
曲美布汀用于治疗胃肠道（GI）运动障碍，如肠易激综合征，包括高运动和低运动功能紊乱。在本期，Tan 等人（2011）研究了曲美布汀对豚鼠结肠运动的浓度依赖性双重作用。作者认为，曲美布汀在较高浓度时主要通过抑制 L 型钙通道来减弱结肠运动，而在较低浓度时通过减少 BK（ca）电流使膜电位去极化，从而增强肌肉收缩。曲美布汀可能是一种合理的胃肠动力调节剂，为开发新的促动力药物提供了思路。进一步研究曲美布汀对胃肠肌肉起搏细胞-间质细胞的作用，将促进其作为胃肠调节剂的治疗获益。
